Every investigational drug in our pipeline represents hope for an essential segment of patients in need of treatment. By targeting known drivers of diseases, we apply precision medicine techniques to develop drugs that show promise of becoming safe, effective therapies.
Kalos Therapeutics mechanism preclinically demonstrated in five laboratories using more than nine different cancer cell lines and three different human cancer xenograft models. Our novel therapy has the potential to treat ascites and edema, both side-effects that lead to pain and often cancer patient death.
All Kalos peptides used in this project were eight amino acids in length, unmodified, and contained all-natural amino acids.
Peptides were tested based on the patented Kalos anti-proliferation motif. The tissue type of the organs implicated in SARs-CoV-2 (Gut Type Tissue) have an affinity to the basic motif that Kalos has patented.
The most visually debilitating form of Age-Related Macular Degeneration (AMD) is the "wet" variety caused by an abnormal growth of blood vessels into the eye's retina. This growth is promoted by vascular endothelial growth factor (VEGF) and treated with VEGF inhibitors such as Lucentis or Avastin. These drugs must be administered by injection into the eye and can produce serious adverse effects.
Recent studies have shown that peptides of the same motif as KTH-222 can also reverse the effects of VEGF in models of wet AMD. Kalos is currently evaluating molecular entities containing a proprietary anti-cellular motif (ACM) as safer and potentially easier to administer therapies for AMD treatment.
For more information on our pipeline, please see our downloadable presentations available on our presentation website page.